Investment Overview I first recommended Repligen in an initiation report published on December 4, 2012 Â at a price of $6.12. Now selling at a price of $223, it has been a good recommendation. My original reason for recommending the stock was that its business model was to support manufacturing of biologics and in particular monoclonal […]
Welcome to SmithonStocks (SOS), home to in-depth financial analysis and research reports with a focus on emerging biotechnology companies.
You now must be a subscriber in order to gain full access to new and featured reports. Please click the "Subscribe" button to register for a SoS subscription. If you are already have a SoS subscription account please log in now.
As always, all blog posts and old reports do not require a subscription to read.
Thank you for visiting SmithonStocks.com.